| Literature DB >> 32721092 |
Alexander Kroemer1, Khalid Khan1, Stuart S Kaufman1, Jiman Kang1, Joshua Weiner1, Anju Duttargi1, Leonid Belyayev1, Chethan Ashokkumar2, Rakesh Sindhi2, Olga A Timofeeva3, Michael Zasloff1, Cal S Matsumoto1, Thomas M Fishbein1.
Abstract
By presenting the first case report of true operational tolerance in an intestinal transplant patient, we aim to demonstrate that tolerance is possible in a field that has been hampered by suboptimal outcomes. Although operational tolerance has been achieved in liver and kidney transplantation, and some intestinal transplant patients have been able to decrease immunosuppression, this is the first instance of true operational tolerance after complete cessation of immunosuppression. A patient received a deceased-donor small intestinal and colon allograft with standard immunosuppressive treatment, achieving excellent graft function after overcoming a graft-versus-host-disease episode 5 months posttransplant. Four years later, against medical advice, the patient discontinued all immunosuppression. During follow-up visits 2 and 3 years after cessation of immunosuppression, the patient exhibited normal graft function with full enteral autonomy and without histological or endoscopic signs of rejection. Mechanistic analysis demonstrated immune competence against third party antigen, with in vitro evidence of donor-specific hyporesponsiveness in the absence of donor macrochimerism. This proof of principle case can stimulate future mechanistic studies on diagnostic and therapeutic strategies, for example, cellular therapy trials, that can lead to minimization or elimination of immunosuppression and, it is hoped, help revitalize the field of intestinal transplantation.Entities:
Keywords: T cell biology; cellular biology; clinical research/practice; immune regulation; immunosuppression/immune modulation; intestinal (allograft) function/dysfunction; intestine/multivisceral transplantation; mucosal immunity; tolerance; translational research/science
Mesh:
Substances:
Year: 2020 PMID: 32721092 PMCID: PMC8274367 DOI: 10.1111/ajt.16224
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086